Paper Details

  1. Home
  2. Paper Details

Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.

Author: LanShih-Kai, OuJiann-Hui, TsaiYuh-Shyan, TzaiTzong-Shin

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Terazosin is an alpha1-selective adrenoceptor blocking agent that has been shown to be effective in treating benign prostatic hyperplasia (BPH). This article discusses the need for an effective and well-tolerated generic formulation of terazosin to improve cost-effectiveness.
Paper Details　
Original Abstract of the Article :
Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH). To improve cost-effectiveness, the development of an effective and well-tolerated generic formulation is need...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2007.04.013

データ提供：米国国立医学図書館（NLM）

Branded vs. Generic Terazosin Hydrochloride: Comparing Effectiveness in Benign Prostatic Hyperplasia

This randomized, open-label, crossover study evaluates the effectiveness of both [branded] and [generic] formulations of [terazosin hydrochloride] in treating [benign prostatic hyperplasia (BPH)]. The researchers found no significant difference in efficacy between the two formulations, suggesting that [generic] versions of [terazosin hydrochloride] can provide comparable clinical benefits to [branded] formulations at potentially lower cost. This study contributes to the growing body of evidence supporting the use of [generic] medications, promoting cost-effectiveness and ensuring access to affordable healthcare.

Generic Medications: A Cost-Effective Option for BPH Treatment

The study's findings provide valuable reassurance regarding the effectiveness of [generic] formulations of [terazosin hydrochloride] in treating [BPH]. The findings suggest that [generic] versions can provide comparable clinical benefits to [branded] formulations at potentially lower cost, offering a more affordable and cost-effective treatment option for patients. This research underscores the importance of considering [generic] medications as viable alternatives, promoting access to affordable healthcare and improving patient affordability.

The Rise of Generic Medications in Healthcare

This study contributes to the growing body of evidence supporting the use of [generic] medications. The findings suggest that [generic] versions of [terazosin hydrochloride] can provide comparable efficacy to [branded] formulations, highlighting the importance of considering [generic] medications as viable alternatives, promoting cost-effectiveness and ensuring access to affordable healthcare. This research reinforces the role of [generic] medications in providing high-quality and cost-effective healthcare options for patients.

Dr. Camel's Conclusion

This research provides valuable insights into the effectiveness of [generic] formulations of [terazosin hydrochloride] in treating [benign prostatic hyperplasia (BPH)]. The findings suggest that [generic] versions can provide comparable clinical benefits to [branded] formulations at potentially lower cost, supporting the use of [generic] medications as a cost-effective and reliable treatment option for patients.

Date :
  1. Date Completed 2007-08-07
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

17617290

DOI: Digital Object Identifier

10.1016/j.clinthera.2007.04.013

Related Literature

Article Analysis
・Effects of terazosin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.